Cargando…

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers

MMV390048 is a novel antimalarial compound that inhibits Plasmodium phosphatidylinositol-4-kinase. The safety, tolerability, pharmacokinetic profile, and antimalarial activity of MMV390048 were determined in healthy volunteers in three separate studies. A first-in-human, double-blind, randomized, pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinxadi, Phumla, Donini, Cristina, Johnstone, Hilary, Langdon, Grant, Wiesner, Lubbe, Allen, Elizabeth, Duparc, Stephan, Chalon, Stephan, McCarthy, James S., Lorch, Ulrike, Chibale, Kelly, Möhrle, Jörg, Barnes, Karen I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179259/ https://www.ncbi.nlm.nih.gov/pubmed/31932368 http://dx.doi.org/10.1128/AAC.01896-19

Ejemplares similares

Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria
por: Mohammed, Rezika, et al.
Publicado: (2023)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics
por: Ghidelli-Disse, Sonja, et al.
Publicado: (2014)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial
por: Thakkar, Nilay, et al.
Publicado: (2018)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
por: de Vries, Laura E., et al.
Publicado: (2022)

A Pharmacokinetic Study of Antimalarial 3,5-Diaryl-2-aminopyridine Derivatives
por: Dambuza, Ntokozo, et al.
Publicado: (2015)

First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection
por: Chughlay, M. Farouk, et al.
Publicado: (2020)

DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum
por: Collins, Katharine A., et al.
Publicado: (2019)

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
por: McCarthy, James S., et al.
Publicado: (2021)

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box
por: Reader, Janette, et al.
Publicado: (2021)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
por: Chughlay, Mohamed Farouk, et al.
Publicado: (2021)

The Candidate Antimalarial Drug MMV665909 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with Quinoline-Derived Antimalarials
por: Vallières, Cindy, et al.
Publicado: (2017)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
por: Mondleki, Enkosi, et al.
Publicado: (2022)

A sustainable, efficient, and potentially cost-effective approach to the antimalarial drug candidate MMV688533
por: Kavthe, Rahul D., et al.
Publicado: (2023)

A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs
por: McCarthy, James S., et al.
Publicado: (2011)

The diaryl-imidazopyridazine anti-plasmodial compound, MMV652103, exhibits anti-breast cancer activity
por: Neumann-Mufweba, Alexis, et al.
Publicado: (2022)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
por: Phyo, Aung Pyae, et al.
Publicado: (2016)

Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers
por: Täubel, Jӧrg, et al.
Publicado: (2021)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay
por: Joubert, Andre, et al.
Publicado: (2022)

Stepwise in vitro screening of MMV pathogen box compounds against Plasmodium falciparum to identify potent antimalarial candidates
por: Mbye, Haddijatou, et al.
Publicado: (2023)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

MMV in partnership: the Eurartesim(®) experience
por: Ubben, David, et al.
Publicado: (2013)

Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection
por: Collins, Katharine A, et al.
Publicado: (2020)

In Vitro Antimalarial Activity of Inhibitors of the Human GTPase Rac1
por: Parapini, Silvia, et al.
Publicado: (2022)

A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Metallocene Antimalarials: The Continuing Quest
por: Blackie, Margaret A. L., et al.
Publicado: (2008)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
por: Duparc, Stephan, et al.
Publicado: (2020)

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells
por: Kikuchi, J, et al.
Publicado: (2008)

Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism
por: Peng, Xi, et al.
Publicado: (2021)

KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
por: Kuhen, Kelli L., et al.
Publicado: (2014)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border
por: Saito, Makoto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8l945hnf02supcf20td530h8bi